Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

INTRODUCTION: Temporary dose modifications, such as reductions or interruptions, may allow patients to better manage adverse events (AEs) associated with pirfenidone use and continue treatment for idiopathic pulmonary fibrosis (IPF). However, the impact of such dosing adjustments on efficacy and saf...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open Respir Res
Main Authors: Nathan, Steven D, Lancaster, Lisa H, Albera, Carlo, Glassberg, Marilyn K, Swigris, Jeffrey J, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Limb, Susan L, Petzinger, Ute, Noble, Paul W
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Interstitial Lung Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089326/
https://ncbi.nlm.nih.gov/pubmed/30116539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados